$PDEX
PRO DEX INC Stock $pdex

$pdex Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000155335022000851 Filed on November 03, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$11.28M	$11.09M	$9.988M
YoY Change	10.9%	11.0%	16.27%
Cost Of Revenue	$8.659M	$8.131M	$6.560M
YoY Change	27.92%	23.95%	28.13%
Gross Profit	$2.623M	$2.956M	$3.428M
YoY Change	-22.94%	-13.77%	-1.49%
Gross Profit Margin	23.25%	26.66%	34.32%
Selling, General & Admin	$1.019M	$1.077M	$1.130M
YoY Change	-14.15%	-4.69%	34.52%
% of Gross Profit	38.85%	36.43%	32.96%
Research & Development	$467.0K	$929.0K	$980.0K
YoY Change	-24.07%	-5.2%	-10.09%
% of Gross Profit	17.8%	31.43%	28.59%
Depreciation & Amortization	$191.0K	$193.0K	$184.0K
YoY Change	4.95%	4.89%	22.67%
% of Gross Profit	7.28%	6.53%	5.37%
Operating Expenses	$1.486M	$2.006M	$2.110M
YoY Change	-17.54%	-4.93%	9.9%
Operating Profit	$1.137M	$950.0K	$1.318M
YoY Change	-29.03%	-27.92%	-15.51%
Interest Expense	$128.0K	$130.0K	$53.00K
YoY Change	-132.65%	145.28%
% of Operating Profit	11.26%	13.68%	4.02%
Other Income/Expense, Net	$2.619M	$344.0K	$53.00K
YoY Change	-1588.07%	549.06%	-131.74%
Pretax Income	$1.174M	$1.294M	$1.371M
YoY Change	-2.98%	-5.62%	-11.55%
Income Tax	$295.0K	$218.0K	$307.0K
% Of Pretax Income	25.13%	16.85%	22.39%
Net Earnings	$879.0K	$1.076M	$1.064M
YoY Change	-4.97%	1.13%	-16.22%
Net Earnings / Revenue	7.79%	9.71%	10.65%
Basic Earnings Per Share	$0.25	$0.30	$0.29
Diluted Earnings Per Share	$0.24	$0.29	$281.7K
COMMON SHARES
Basic Shares Outstanding	3.580M shares	3.619M shares	3.651M shares
Diluted Shares Outstanding	3.652K shares	3.695M shares	3.777M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.242M	$5.500M	$6.683M
YoY Change	-50.07%	-17.7%	-12.07%
Cash & Equivalents	$382.0K	$2.798M	$5.177M
Short-Term Investments	$2.860M	$2.702M	$1.506M
Other Short-Term Assets	$1.664M	$1.515M	$335.0K
YoY Change	13.97%	352.24%	-30.21%
Inventory	$15.14M	$15.66M	$8.907M
Prepaid Expenses
Receivables	$12.20M	$11.05M	$10.09M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$31.39M	$31.84M	$26.02M
YoY Change	20.31%	22.36%	15.43%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.203M	$4.852M	$13.47M
YoY Change	-61.24%	-63.97%	145.28%
Goodwill
YoY Change
Intangibles	$98.00K	$108.0K
YoY Change
Long-Term Investments	$1.726M	$1.889M	$1.656M
YoY Change	-11.03%	14.07%	-28.31%
Other Assets	$42.00K	$42.00K	$530.0K
YoY Change	-91.68%	-92.08%	76.67%
Total Long-Term Assets	$16.19M	$16.13M	$15.85M
YoY Change	1.04%	1.79%	91.85%
TOTAL ASSETS
Total Short-Term Assets	$31.39M	$31.84M	$26.02M
Total Long-Term Assets	$16.19M	$16.13M	$15.85M
Total Assets	$47.58M	$47.97M	$41.87M
YoY Change	12.98%	14.57%	35.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.364M	$3.549M	$2.476M
YoY Change	45.31%	43.34%	35.3%
Accrued Expenses	$3.314M	$3.245M	$2.195M
YoY Change	82.89%	47.84%	24.72%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.110M	$3.297M	$1.248M
YoY Change	146.83%	164.18%	89.09%
Total Short-Term Liabilities	$11.67M	$11.67M	$6.212M
YoY Change	95.36%	87.91%	39.6%
LONG-TERM LIABILITIES
Long-Term Debt	$9.590M	$9.922M	$11.22M
YoY Change	-12.01%	-11.56%	260.74%
Other Long-Term Liabilities	$1.850M	$1.954M	$3.051M
YoY Change	-42.88%	-35.96%	-4.06%
Total Long-Term Liabilities	$11.44M	$11.88M	$14.27M
YoY Change	-19.08%	-16.78%	126.87%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.67M	$11.67M	$6.212M
Total Long-Term Liabilities	$11.44M	$11.88M	$14.27M
Total Liabilities	$23.11M	$23.55M	$20.48M
YoY Change	14.9%	14.97%	90.53%
SHAREHOLDERS EQUITY
Retained Earnings	$17.94M	$17.06M	$14.26M
YoY Change	16.97%	19.67%	75.54%
Common Stock	$6.533M	$7.354M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$24.47M	$24.42M
YoY Change
Total Liabilities & Shareholders Equity	$47.58M	$47.97M	$41.87M
YoY Change	12.98%	14.57%	35.93%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	$879.0K	$1.076M	$1.064M
YoY Change	-4.97%	1.13%	-16.22%
Depreciation, Depletion And Amortization	$191.0K	$193.0K	$184.0K
YoY Change	4.95%	4.89%	22.67%
Cash From Operating Activities	-$395.0K	$2.892M	$2.701M
YoY Change	-126.02%	7.07%	-403.48%
INVESTING ACTIVITIES
Capital Expenditures	$509.0K	$178.0K	-$848.0K
YoY Change	-327.23%	-120.99%	842.22%
Acquisitions
YoY Change
Other Investing Activities	$1.000K	$88.00K	-$26.00K
YoY Change	-100.3%	-438.46%	-123.64%
Cash From Investing Activities	-$508.0K	-$90.00K	-$874.0K
YoY Change	-8.63%	-89.7%	-3013.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.513M	-$853.0K	-371.0K
YoY Change	70.57%	129.92%	3.06%
NET CHANGE
Cash From Operating Activities	-395.0K	$2.892M	2.701M
Cash From Investing Activities	-508.0K	-$90.00K	-874.0K
Cash From Financing Activities	-1.513M	-$853.0K	-371.0K
Net Change In Cash	-2.416M	$1.949M	1.456M
YoY Change	-3321.33%	33.86%	-219.34%
FREE CASH FLOW
Cash From Operating Activities	-$395.0K	$2.892M	$2.701M
Capital Expenditures	$509.0K	$178.0K	-$848.0K
Free Cash Flow	-$904.0K	$2.714M	$3.549M
YoY Change	-151.89%	-23.53%	-543.63%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q3	dei	Entity Central Index Key EntityCentralIndexKey	0000788920
CY2022Q3	dei	Amendment Flag AmendmentFlag	false
CY2022Q3	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2022Q3	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022Q3	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q3	us-gaap	Realized Gain Loss On Marketable Securities Cost Method Investments And Other Investments RealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments		usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity		usd
CY2022Q3	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments		usd
CY2022Q3	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
CY2021Q3	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities		usd
CY2021Q3	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt		usd
CY2021Q3	pdex	Payment Of Employee Payroll Taxes On Net Issuance Of Common Stock PaymentOfEmployeePayrollTaxesOnNetIssuanceOfCommonStock		usd
CY2022Q3	pdex	Cashless Stock Option Exercise CashlessStockOptionExercise		usd
CY2021Q3	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2021Q3	pdex	Amounts Reclassified To Revenue AmountsReclassifiedToRevenue		usd
CY2022Q3	dei	Document Type DocumentType	10-Q
CY2022Q3	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q3	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
CY2022Q3	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q3	dei	Entity File Number EntityFileNumber	0-14942
CY2022Q3	dei	Entity Registrant Name EntityRegistrantName	PRO-DEX, INC.
CY2022Q3	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	CO
CY2022Q3	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-1261240
CY2022Q3	dei	Entity Address Address Line1 EntityAddressAddressLine1	2361 McGaw Avenue
CY2022Q3	dei	Entity Address City Or Town EntityAddressCityOrTown	Irvine
CY2022Q3	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022Q3	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92614
CY2022Q3	dei	City Area Code CityAreaCode	(949)
CY2022Q3	dei	Local Phone Number LocalPhoneNumber	769-3200
CY2022Q3	dei	Security12b Title Security12bTitle	Common Stock, no par value
CY2022Q3	dei	Trading Symbol TradingSymbol	PDEX
CY2022Q3	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q3	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q3	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q3	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q3	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q3	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q3	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3580316	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2798000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	849000	usd
CY2022Q3	us-gaap	Short Term Investments ShortTermInvestments	813000	usd
CY2022Q2	us-gaap	Short Term Investments ShortTermInvestments	755000	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2000	usd
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11045000	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15384000	usd
CY2022Q3	us-gaap	Deferred Costs Current DeferredCostsCurrent	587000	usd
CY2022Q2	us-gaap	Deferred Costs Current DeferredCostsCurrent	710000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	15664000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	12678000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	928000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	790000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	31835000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	31166000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	6319000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	6343000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4852000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4833000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2156000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2248000	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	108000	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	118000	usd
CY2022Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	764000	usd
CY2022Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	797000	usd
CY2022Q3	us-gaap	Long Term Investments LongTermInvestments	1889000	usd
CY2022Q2	us-gaap	Long Term Investments LongTermInvestments	1779000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	42000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	42000	usd
CY2022Q3	us-gaap	Assets Assets	47965000	usd
CY2022Q2	us-gaap	Assets Assets	47326000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3549000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	3761000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3245000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2751000	usd
CY2022Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	731000	usd
CY2022Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	544000	usd
CY2022Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	851000	usd
CY2022Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1013000	usd
CY2022Q3	us-gaap	Notes Payable Current NotesPayableCurrent	3297000	usd
CY2022Q2	us-gaap	Notes Payable Current NotesPayableCurrent	3285000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	11673000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	11354000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1954000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2054000	usd
CY2022Q3	us-gaap	Notes Payable NotesPayable	9922000	usd
CY2022Q2	us-gaap	Notes Payable NotesPayable	10250000	usd
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	11876000	usd
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	12304000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	23549000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	23658000	usd
CY2022Q3	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2022Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3606422	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3606422	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3596131	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3596131	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	7354000	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	7682000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	17062000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	15986000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	24416000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	23668000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	47965000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	47326000	usd
CY2022Q3	us-gaap	Revenues Revenues	11087000	usd
CY2021Q3	us-gaap	Revenues Revenues	9988000	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	8131000	usd
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	6560000	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	2956000	usd
CY2021Q3	us-gaap	Gross Profit GrossProfit	3428000	usd
CY2022Q3	us-gaap	Selling Expense SellingExpense	53000	usd
CY2021Q3	us-gaap	Selling Expense SellingExpense	37000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1024000	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1093000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	929000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	980000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	2006000	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	2110000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	950000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	1318000	usd
CY2022Q3	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	218000	usd
CY2021Q3	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	24000	usd
CY2022Q3	us-gaap	Realized Gain Loss On Marketable Securities Cost Method Investments And Other Investments RealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments	6000	usd
CY2022Q3	us-gaap	Unrealized Gain Loss On Marketable Securities Cost Method Investments And Other Investments UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments	250000	usd
CY2021Q3	us-gaap	Unrealized Gain Loss On Marketable Securities Cost Method Investments And Other Investments UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments	149000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	130000	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	120000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	344000	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	53000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1294000	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1371000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	218000	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	307000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	1076000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	1064000	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.30
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.29
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.29
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.28
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3616392	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3651334	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3694959	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3777118	shares
CY2022Q3	us-gaap	Weighted Average Number Of Limited Partnership And General Partnership Unit Outstanding Basic And Diluted WeightedAverageNumberOfLimitedPartnershipAndGeneralPartnershipUnitOutstandingBasicAndDiluted	3606422	shares
CY2021Q3	us-gaap	Weighted Average Number Of Limited Partnership And General Partnership Unit Outstanding Basic And Diluted WeightedAverageNumberOfLimitedPartnershipAndGeneralPartnershipUnitOutstandingBasicAndDiluted	3666319	shares
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	23668000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	1076000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	1064000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	24416000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	21383000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	1076000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	1064000	usd
CY2022Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	193000	usd
CY2021Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	184000	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	207000	usd
CY2021Q3	us-gaap	Share Based Compensation ShareBasedCompensation	300000	usd
CY2022Q3	us-gaap	Unrealized Gain Loss On Marketable Securities Cost Method Investments And Other Investments UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments	250000	usd
CY2021Q3	us-gaap	Unrealized Gain Loss On Marketable Securities Cost Method Investments And Other Investments UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments	149000	usd
CY2022Q3	pdex	Noncash Lease Expense NoncashLeaseExpense	2000	usd
CY2021Q3	pdex	Noncash Lease Expense NoncashLeaseExpense	6000	usd
CY2022Q3	us-gaap	Amortization Of Deferred Loan Origination Fees Net AmortizationOfDeferredLoanOriginationFeesNet	-2000	usd
CY2021Q3	us-gaap	Amortization Of Deferred Loan Origination Fees Net AmortizationOfDeferredLoanOriginationFeesNet	-2000	usd
CY2022Q3	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	6000	usd
CY2022Q3	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	32000	usd
CY2022Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	2000	usd
CY2021Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	5000	usd
CY2022Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4337000	usd
CY2021Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-834000	usd
CY2022Q3	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-123000	usd
CY2021Q3	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-9000	usd
CY2022Q3	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2986000	usd
CY2021Q3	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	470000	usd
CY2022Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	138000	usd
CY2021Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-284000	usd
CY2022Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	273000	usd
CY2021Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	177000	usd
CY2022Q3	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-162000	usd
CY2021Q3	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	143000	usd
CY2022Q3	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	187000	usd
CY2021Q3	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	312000	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2892000	usd
CY2021Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2701000	usd
CY2022Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	178000	usd
CY2021Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	848000	usd
CY2021Q3	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	14000	usd
CY2021Q3	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	12000	usd
CY2022Q3	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	88000	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-90000	usd
CY2021Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-874000	usd
CY2022Q3	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1318000	usd
CY2021Q3	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	306000	usd
CY2022Q3	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	1000000	usd
CY2022Q3	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	42000	usd
CY2021Q3	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	30000	usd
CY2022Q3	pdex	Payment Of Employee Payroll Taxes On Net Issuance Of Common Stock PaymentOfEmployeePayrollTaxesOnNetIssuanceOfCommonStock	-223000	usd
CY2022Q3	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	354000	usd
CY2021Q3	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	95000	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-853000	usd
CY2021Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-371000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1949000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1456000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	849000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3721000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2798000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5177000	usd
CY2021Q3	pdex	Cashless Stock Option Exercise CashlessStockOptionExercise	45000	usd
CY2022Q3	us-gaap	Interest Paid Net InterestPaidNet	89000	usd
CY2021Q3	us-gaap	Interest Paid Net InterestPaidNet	121000	usd
CY2022Q3	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	241000	usd
CY2022Q3	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_803_eus-gaap--NatureOfOperations_zWKcsP6vp0g2" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">NOTE 2. <span id="xdx_822_z5ccuEuLbVL9">DESCRIPTION OF BUSINESS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 3pc"><span id="a_DV_M441"/><span id="a_DV_M442"/> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 3pc">We specialize in the design, development and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. We have patented adaptive torque-limiting software and proprietary sealing solutions which appeal to our customers, primarily medical device distributors. We also manufacture and sell rotary air motors to a wide range of industries.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 3pc"><span style="letter-spacing: -0.05pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 3pc"><span style="letter-spacing: -0.05pt">In August 2020, we formed a wholly owned subsidiary, PDEX Franklin, LLC (“PDEX Franklin”), to hold title for an approximate 25,000 square foot industrial building in Tustin, California (the “Franklin Property”) that we acquired on November 6, 2020, in order to allow for the continued growth of our business. The condensed consolidated financial statements include the accounts of the Company and PDEX Franklin and all significant inter-company accounts and transactions have been eliminated. This subsidiary has no separate operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 3pc"> </p>
CY2022Q3	pdex	Overtime Revenue Recognition OvertimeRevenueRecognition	907000	usd
CY2021Q3	pdex	Overtime Revenue Recognition OvertimeRevenueRecognition	196000	usd
CY2022Q3	pdex	Pointintime Revenue Recognition PointintimeRevenueRecognition	10180000	usd
CY2021Q3	pdex	Pointintime Revenue Recognition PointintimeRevenueRecognition	9792000	usd
CY2022Q3	us-gaap	Revenues Revenues	11087000	usd
CY2021Q3	us-gaap	Revenues Revenues	9988000	usd
CY2022Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	551000	usd
CY2021Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	usd
CY2022Q3	us-gaap	Deferred Revenue DeferredRevenue	851000	usd
CY2022Q2	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	710000	usd
CY2021Q2	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	212000	usd
CY2022Q3	us-gaap	Accretion Expense AccretionExpense	333000	usd
CY2021Q3	us-gaap	Accretion Expense AccretionExpense	96000	usd
CY2022Q3	pdex	Amounts Reclassified To Cost Of Sales AmountsReclassifiedToCostOfSales	-448000	usd
CY2021Q3	pdex	Amounts Reclassified To Cost Of Sales AmountsReclassifiedToCostOfSales	-111000	usd
CY2022Q3	pdex	Amounts Allocated To Discounts For Standalone Selling Price AmountsAllocatedToDiscountsForStandaloneSellingPrice	-8000	usd
CY2021Q3	pdex	Amounts Allocated To Discounts For Standalone Selling Price AmountsAllocatedToDiscountsForStandaloneSellingPrice	-12000	usd
CY2022Q3	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	587000	usd
CY2021Q3	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	185000	usd
CY2022Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1013000	usd
CY2021Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	150000	usd
CY2022Q3	us-gaap	Proceeds From Customers For Progress Payments ProceedsFromCustomersForProgressPayments	389000	usd
CY2021Q3	us-gaap	Proceeds From Customers For Progress Payments ProceedsFromCustomersForProgressPayments	143000	usd
CY2022Q3	pdex	Amounts Reclassified To Revenue AmountsReclassifiedToRevenue	-551000	usd
CY2022Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	851000	usd
CY2021Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	293000	usd
CY2022Q3	us-gaap	Short Term Investments ShortTermInvestments	813000	usd
CY2022Q2	us-gaap	Short Term Investments ShortTermInvestments	755000	usd
CY2022Q3	us-gaap	Long Term Investments LongTermInvestments	1889000	usd
CY2022Q2	us-gaap	Long Term Investments LongTermInvestments	1779000	usd
CY2022Q3	us-gaap	Marketable Securities MarketableSecurities	2702000	usd
CY2022Q2	us-gaap	Marketable Securities MarketableSecurities	2534000	usd
CY2022Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	2714000	usd
CY2022Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	2796000	usd
CY2022Q3	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	12000	usd
CY2022Q3	pdex	Marketable Securities Unrealized Loss MarketableSecuritiesUnrealizedLoss	325000	usd
CY2022Q3	pdex	Marketable Securities Unrealized Gain MarketableSecuritiesUnrealizedGain	313000	usd
CY2022Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	262000	usd
CY2022Q2	pdex	Marketable Securities Unrealized Loss MarketableSecuritiesUnrealizedLoss	369000	usd
CY2022Q2	pdex	Marketable Securities Unrealized Gain MarketableSecuritiesUnrealizedGain	107000	usd
CY2022Q3	pdex	Investment In Common Stock Affiliated With Company Board Members InvestmentInCommonStockAffiliatedWithCompanyBoardMembers	813000	usd
CY2022Q2	pdex	Investment In Common Stock Affiliated With Company Board Members InvestmentInCommonStockAffiliatedWithCompanyBoardMembers	755000	usd
CY2022Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	7641000	usd
CY2022Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	6323000	usd
CY2022Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	4104000	usd
CY2022Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	3463000	usd
CY2022Q3	pdex	Inventory Sub Assemblies InventorySubAssemblies	2183000	usd
CY2022Q2	pdex	Inventory Sub Assemblies InventorySubAssemblies	2118000	usd
CY2022Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1736000	usd
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	774000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	15664000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	12678000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	100000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	90000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	108000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	118000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Four FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour	27000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P3Y
CY2022Q3	us-gaap	Product Warranty Expense ProductWarrantyExpense	366000	usd
CY2021Q3	us-gaap	Product Warranty Expense ProductWarrantyExpense	340000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	1064000	usd
CY2022Q3	pdex	Weightedaverage Shares Outstanding Diluted WeightedaverageSharesOutstandingDiluted	3616	shares
CY2021Q3	pdex	Weightedaverage Shares Outstanding Diluted WeightedaverageSharesOutstandingDiluted	3651	shares
CY2022Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	340000	usd
CY2021Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	221000	usd
CY2022Q3	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	54000	usd
CY2021Q3	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	32000	usd
CY2022Q3	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	14000	usd
CY2021Q3	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	-8000	usd
CY2022Q3	pdex	Product Warranty Accrual Amortization And Utilization ProductWarrantyAccrualAmortizationAndUtilization	-42000	usd
CY2021Q3	pdex	Product Warranty Accrual Amortization And Utilization ProductWarrantyAccrualAmortizationAndUtilization	-13000	usd
CY2022Q3	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	366000	usd
CY2021Q3	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	232000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	1076000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	1064000	usd
CY2022Q3	pdex	Weightedaverage Shares Outstanding Basic WeightedaverageSharesOutstandingBasic	3616	shares
CY2021Q3	pdex	Weightedaverage Shares Outstanding Basic WeightedaverageSharesOutstandingBasic	3651	shares
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.30
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.29
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	1076000	usd
CY2022Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	79	shares
CY2021Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	126	shares
CY2022Q3	pdex	Weighted Average Shares Used In Calculation Of Diluted Earnings Per Share WeightedAverageSharesUsedInCalculationOfDilutedEarningsPerShare	3695	shares
CY2021Q3	pdex	Weighted Average Shares Used In Calculation Of Diluted Earnings Per Share WeightedAverageSharesUsedInCalculationOfDilutedEarningsPerShare	3777	shares
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.29
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.28
CY2022Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5000	usd
CY2021Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	51000	usd
CY2022Q3	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.17	pure
CY2021Q3	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.22	pure
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1500	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.14
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P0Y4M6D
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	23000	usd
CY2022Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	5000	shares
CY2021Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	25000	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	1.73
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	1.80
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	381000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	519000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	535000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	551000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	567000	usd
CY2022Q3	pdex	Major Customers Suppliers Description MajorCustomersSuppliersDescription	Amounts owed to the fiscal 2022 significant suppliers at September 30, 2022 totaled $970,000, $266,000 and $368,000, respectively, and at June 30, 2022 totaled $721,000, $430,000 and $372,000, respectively.
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	388000	usd
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0553	pure
CY2022Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	123000	usd
CY2022Q3	pdex	Operating Lease Payments Other OperatingLeasePaymentsOther	12000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	143000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2696000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	353000	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2343000	usd

Files In Submission

Name	View Source	Status
0001553350-22-000851-index-headers.html	Edgar Link	pending
0001553350-22-000851-index.html	Edgar Link	pending
0001553350-22-000851.txt	Edgar Link	pending
0001553350-22-000851-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pdex-20220930.xsd	Edgar Link	pending
pdex_10q.htm	Edgar Link	pending
pdex_ex31z1.htm	Edgar Link	pending
pdex_ex31z2.htm	Edgar Link	pending
pdex_ex32z1.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
pdex-20220930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
pdex-20220930_lab.xml	Edgar Link	unprocessable
pdex-20220930_cal.xml	Edgar Link	unprocessable
pdex-20220930_def.xml	Edgar Link	unprocessable
pdex_10q_htm.xml	Edgar Link	completed
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PDEX
PRO DEX INC Stock $pdex

2022 Q4 Form 10-Q Financial Statement

#000155335022000851 Filed on November 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PDEX PRO DEX INC Stock $pdex

2022 Q4 Form 10-Q Financial Statement

#000155335022000851 Filed on November 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PDEX
PRO DEX INC Stock $pdex